西尼必利联合米曲菌胰酶片治疗功能性消化不良及对患者胃肠动力指标的影响

Effect of Cinitapride Combined with Oryz-Aspergillus Enzyme and Pancreatin Tablets on Functional Dyspepsia and Gastrointestinal Motility Indexes

目的:探讨西尼必利联合米曲菌胰酶片治疗功能性消化不良的治疗效果及对患者胃肠动力指标的影响。方法:选取2020年1月至2021年12月泉州海峡医院收治的140例功能性消化不良患者,分为观察组、对照组,各70例。对照组以米曲菌胰酶片治疗,观察组以西尼必利联合米曲菌胰酶片治疗。综合评估两组患者的临床疗效、症状评分、胃肠动力指标、炎症因子水平、治疗安全性。结果:观察组临床总有效率为91.43%(64/70),对照组总有效率为75.71%(53/70),观察组高于对照组(P<0.05)。治疗后观察组患者症状评分均低于对照组(P<0.05)。治疗后观察组患者胃肠动力学指标包括胃排空率(GER)、胃体蠕动次数(FA)、胃窦收缩次数(FB)均高于对照组(P<0.05)。治疗后观察组患者的血清水通道蛋白3(AQP3)、蛋白酶激活受体2蛋白(PAR2)、分泌型卷曲相关蛋白1(SFRP1)均低于对照组(P<0.05)。治疗期间观察组、对照组不良反应发生率分别为12.86%(9/70)、8.57%(6/70)(P>0.05)。结论:西尼必利联合米曲菌胰酶片治疗功能性消化不良疗效较好,可改善患者的症状评分,提高患者的胃肠动力学,抑制各项炎症因子表达,治疗安全性良好。

Objective:To study the therapeutic effect of cinitapride combined with oryz-aspergillus enzyme and pancreatin tablets in the treatment of functional dyspepsia and its effect on gastrointestinal motility indexes.Methods:140 patients with functional dyspepsia treated in Haixia Hospital from January 2020 to December 2021 randomly divided into observation,control group,with 70 cases in each group.The control group was treated with oryz-aspergillus enzyme and pancreatin tablets,and the observation group was treated with cinitapride combined with oryz-aspergillus enzyme and pancreatin tablets.The clinical efficacy,symptom score,gastrointestinal motility index,inflammatory factor level and treatment safety of the two groups were comprehensively evaluated.Results:The total effective rate was 91.43%(64/70)in the observation group and 75.71%(53/70)in the control group,which was higher in the observation group than in the control group(P<0.05).After treatment,the symptom scores of the observation group,including early satiety,belching,abdominal distension,abdominal pain and loss of appetite,were lower than those of the control group(P<0.05).After treatment,the gastrointestinal dynamic indexes including gastric emptying rate(GER),gastric body peristalsis times(FA)and gastric antrum contraction times(FB)in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of serum aquaporin 3(AQP3),protease activated receptor 2(PAR2)and secretory curl associated protein 1(SFRP1)in the observation group were lower than those in the control group(P<0.05).During the treatment,the incidence of adverse reactions in the observation group and the control group was 12.86%(9/70)and 8.57%(6/70)(P>0.05).Conclusion:Cinitapride combined with oryz-aspergillus enzyme and pancreatin tablets is effective in the treatment of functional dyspepsia.It can improve the symptom score of patients,improve the gastrointestinal dynamics of patients,inhibit the expression of various inflammatory factors.The treatment is safe and can be recommended clinically.